AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38258274 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 60 mg (single-ascending dose study)
Number of subjects: 149
Study 38258274 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9567 10 mg (multiple-ascending dose study)
Number of subjects: 149
Study 38258274 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 20 mg (multiple-ascending dose study)
Number of subjects: 149
Study 38258274 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9567 20 mg, 40 mg, 80 mg, or 125 mg (multiple-ascending dose study)
Number of subjects: 149
Study 38258274 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 5 mg, 20 mg, or 40 mg (multiple-ascending dose study)
Number of subjects: 149
Study 38258274 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9567 (up to 80 mg)
Number of subjects: 149
Study 38258274 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 5 mg
Number of subjects: 149
Study 38258329 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² followed by cytarabine
Number of subjects: 0
Study 38258362 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet reactivity measured using VerifyNow P2Y in patients with reduced LVEF (REF)
Number of subjects: 9319
Study 38258362 — intervention group
Group type: COMPARATOR
Intervention: Platelet reactivity measured using VerifyNow P2Y in patients with preserved LVEF (PEF)
Number of subjects: 9319
Study 38258362 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) status in patients with LV dysfunction
Number of subjects: 9319
Study 38258369 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 0
Study 38258369 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 0
Study 38258369 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE-DAS remission and LDA
Number of subjects: 0
Study 38258369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38258434 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 38258434 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 0
Study 38258563 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bolus of recombinant staphylokinase (r-SAK) before PCI
Number of subjects: 200
Study 38258563 — intervention group
Group type: COMPARATOR
Intervention: Normal saline before PCI
Number of subjects: 200
Study 38258563 — intervention group
Group type: EXPERIMENTAL
Intervention: r-SAK
Number of subjects: 200
Study 38258563 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 200
Study 38258566 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure (SMBP) with usual care
Number of subjects: 3291
Study 38258566 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3291
Study 38258566 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring system
Number of subjects: 3291
Study 38258600 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε2 genotype
Number of subjects: 4184
Study 38258600 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4184
Study 38258673 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-focused physical therapy
Number of subjects: 184
Study 38258673 — intervention group
Group type: COMPARATOR
Intervention: Spine-focused physical therapy
Number of subjects: 184
Study 38258677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (6 mg)
Number of subjects: 99
Study 38258677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 38258678 — intervention group
Group type: COMPARATOR
Intervention: Reference tocilizumab
Number of subjects: 621
Study 38258678 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT1806/BIIB800
Number of subjects: 621
Study 38258823 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation for iCCA
Number of subjects: 0
Study 38258823 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapies
Number of subjects: 0
Study 38258823 — intervention group
Group type: EXPERIMENTAL
Intervention: New molecular biomarkers
Number of subjects: 0
Study 38258823 — intervention group
Group type: EXPERIMENTAL
Intervention: New technologies and strategies for graft availability
Number of subjects: 0
Study 38258997 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver surgery
Number of subjects: 2159
Study 38259250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610) 225 mg tablet QD
Number of subjects: 44
Study 38259250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelabresib (CPI-0610)
Number of subjects: 44
Study 38259270 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinqiao powder-maxing Ganshi decoction
Number of subjects: 0
Study 38259270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38259304 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 8741
Study 38259304 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban therapy
Number of subjects: 8741
Study 38259304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin level
Number of subjects: 8741
Study 38259304 — intervention group
Group type: EXPERIMENTAL
Intervention: High WBC count
Number of subjects: 8741
Study 38259304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior myocardial infarction (MI)
Number of subjects: 8741
Study 38259304 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 8741
Study 38259304 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 8741
Study 38259459 — intervention group
Group type: EXPERIMENTAL
Intervention: LPCAT level in patients with SCAP
Number of subjects: 299
Study 38259459 — intervention group
Group type: EXPERIMENTAL
Intervention: LPCAT level combined with PSI scores or CURB-65
Number of subjects: 299
Study 38259459 — intervention group
Group type: EXPERIMENTAL
Intervention: On admission LPCAT level
Number of subjects: 299
Study 38259459 — intervention group
Group type: EXPERIMENTAL
Intervention: LPCAT value combined with CURB-65 or PSI
Number of subjects: 299
Study 38259542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric cGVHD Symptom Scale (PCSS)
Number of subjects: 180
Study 38259555 — intervention group
Group type: EXPERIMENTAL
Intervention: Brunnsviken brief quality of life inventory (BBQ)
Number of subjects: 0
Study 38259740 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVA-MENTE program (active breaks) consisting of a 4-min, 30-s video with moderate to vigorous-intensity physical activity, taken 6 times a day for 6 weeks.
Number of subjects: 0
Study 38259740 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 38259747 — intervention group
Group type: EXPERIMENTAL
Intervention: sLiFE group intervention (strength and balance principles)
Number of subjects: 650
Study 38259747 — intervention group
Group type: COMPARATOR
Intervention: Standard health advice
Number of subjects: 650
Study 38259873 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreDISTparticipation
Number of subjects: 29
Study 38259873 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study 38260556 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (XOI) treatment for 48 weeks
Number of subjects: 49
Study 38260556 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 49
Study 38260556 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (control)
Number of subjects: 49
Study 38260663 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg daily for 16 weeks
Number of subjects: 12
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: RV injury (isolated RV dilation)
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: RV injury (dysfunction without RV dilation)
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: RV injury (dysfunction with RV dilation)
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: RV injury (acute cor pulmonale)
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: RV injury (overall)
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-28 mortality (with RV injury)
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RV dysfunction with RV dilation or ACP
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo RV injury
Number of subjects: 118
Study 38261092 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo RV injury after Day-14
Number of subjects: 118
Study 38261093 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging (LSCI) during adenosine induced cardiac arrest (AiCA)
Number of subjects: 0
Study 38261313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib (400 mg once daily, orally)
Number of subjects: 34
Study 38261316 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab at 10 mg/kg on days 1 and 15, ramucirumab at 8 mg/kg on days 1 and 15, paclitaxel at 80 mg/m2 on days 1, 8, and 15 every 4 weeks.
Number of subjects: 60
Study 38261316 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab with paclitaxel plus ramucirumab
Number of subjects: 60
Study 38261319 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care (PPC)
Number of subjects: 264
Study 38261319 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 264
Study 38261323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of naloxone (4 mg/0.1 mL) at 0, 2.5, 5, and 7.5 minutes
Number of subjects: 21
Study 38261323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of naloxone at 0 and 2.5 minutes
Number of subjects: 21
Study 38261323 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of naloxone at 0 and 2.5 minutes (control)
Number of subjects: 21
Study 38261323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of naloxone at 0, 2.5, 5, and 7.5 minutes (test)
Number of subjects: 21
Study 38261323 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of naloxone at 0 and 2.5 minutes (test)
Number of subjects: 21
Study 38261372 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected devices for home monitoring and education for early detection of pulmonary exacerbations (PEx).
Number of subjects: 20
Study 38261390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus low disease activity state (LLDAS) attained at least once
Number of subjects: 3811
Study 38261390 — intervention group
Group type: EXPERIMENTAL
Intervention: LLDAS for at least 50% of observed time
Number of subjects: 3811
Study 38261390 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission attained
Number of subjects: 3811
Study 38261390 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission for at least 50% of observed time
Number of subjects: 3811
Study 38261390 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified remission glucocorticoid threshold (<5.0 mg/day prednisolone)
Number of subjects: 3811
Study 38261390 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid-free remission
Number of subjects: 3811
Study 38261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant positivity at inclusion
Number of subjects: 168
Study 38261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental insufficiency
Number of subjects: 168
Study 38261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing maternal hypertension
Number of subjects: 168
Study 38261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid history
Number of subjects: 168
Study 38261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiphospholipid antibody positivity
Number of subjects: 168
Study 38261392 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm delivery at 34 weeks or earlier
Number of subjects: 168
Study 38261444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and Uprosertib starting at 50 mg daily (doublet cohort)
Number of subjects: 27
Study 38261444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily, Trametinib 2 mg daily, and Uprosertib 75 mg daily (triplet cohort)
Number of subjects: 27
Study 38261469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive elastic tape
Number of subjects: 23
Study 38261469 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 23
Study 38261535 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer
Number of subjects: 1480
Study 38261535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1480
Study 38261536 — intervention group
Group type: COMPARATOR
Intervention: Typical dialysis with dialysate temperature at 37°C (TD)
Number of subjects: 10
Study 38261536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dialysis with dialysate temperature at 35°C
Number of subjects: 10
Study 38261536 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical HD combined with a single exercise bout
Number of subjects: 10
Study 38261536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dialysis combined with a single exercise bout
Number of subjects: 10
Study 38261579 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of azithromycin (20 mg/kg)
Number of subjects: 32877
Study 38261630 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Carbon Dioxide Removal (ECCO2R)
Number of subjects: 0
Study 38261630 — intervention group
Group type: COMPARATOR
Intervention: Invasive Ventilation
Number of subjects: 0
Study 38261781 — intervention group
Group type: EXPERIMENTAL
Intervention: Various techniques used to assess bone health; specific interventions not detailed.
Number of subjects: 0
Study 38261781 — intervention group
Group type: COMPARATOR
Intervention: Not applicable; no specific intervention mentioned.
Number of subjects: 0
Study 38261785 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvideos
Number of subjects: 60
Study 38261785 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lectures
Number of subjects: 60
Study 38261893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led program for HCV treatment
Number of subjects: 40
Study 38261893 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral medications (DAAs) initiation
Number of subjects: 40
Study 38261893 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of DAAs treatment
Number of subjects: 40
Study 38261893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cure (sustained virologic response)
Number of subjects: 40
Study 38261893 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction with pharmacist experience
Number of subjects: 40
Study 38261914 — intervention group
Group type: EXPERIMENTAL
Intervention: CO > 11 ppm in active smokers
Number of subjects: 1379
Study 38261914 — intervention group
Group type: EXPERIMENTAL
Intervention: CO > 11 ppm in overall population
Number of subjects: 1379
Study 38261914 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking in overall population
Number of subjects: 1379
Study 38261958 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg intravenously, day one) + Apatinib (250 mg, q.d., five continuous days per week) + Nab-paclitaxel (135 mg/m2)
Number of subjects: 64
Study 38261969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) plus Pembrolizumab
Number of subjects: 41
Study 38261983 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + apalutamide
Number of subjects: 503
Study 38261983 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + apalutamide + AAP
Number of subjects: 503
Study 38261983 — intervention group
Group type: COMPARATOR
Intervention: ADT control
Number of subjects: 503
Study 38262005 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion block (SPGB)
Number of subjects: 83
Study 38262005 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 83
Study 38262066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily)
Number of subjects: 640
Study 38262066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study 38262242 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanidatamab (ZW25)
Number of subjects: 16
Study 38262275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low endothelial shear stress (ESS), high ESS gradient (ESSG), and high plaque structural stress (PSS) heterogeneity index (HI)
Number of subjects: 67
Study 38262275 — intervention group
Group type: EXPERIMENTAL
Intervention: High PSS HI
Number of subjects: 67
Study 38262275 — intervention group
Group type: EXPERIMENTAL
Intervention: High ESSG
Number of subjects: 67
Study 38262275 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque burden >70%
Number of subjects: 67
Study 38262275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low ESS, high ESSG, and high PSS HI with plaque burden >70%
Number of subjects: 67
Study 38262397 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week progressive resistance training protocol three times per week
Number of subjects: 11
Study 38262428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g intravenous once within 12 hours following tracheal intubation
Number of subjects: 345
Study 38262428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 38262462 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic management
Number of subjects: 0
Study 38262617 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassurance, education, lifestyle measures plus pharmacological strategies
Number of subjects: 111
Study 38262642 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units incobotulinumtoxin-A
Number of subjects: 80
Study 38262642 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study 38262657 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised care at 'Maison des Femmes' (MdF)
Number of subjects: 67
Study 38262657 — intervention group
Group type: COMPARATOR
Intervention: Care at uncoordinated structures
Number of subjects: 67
Study 38262864 — intervention group
Group type: EXPERIMENTAL
Intervention: Helfer skin tap technique
Number of subjects: 64
Study 38262864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 38262982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiko platform
Number of subjects: 1514
Study 38263021 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril 5/10 mg
Number of subjects: 560
Study 38263021 — intervention group
Group type: COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 10/12.5 mg
Number of subjects: 560
Study 38263053 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (structured exercise training, nutritional counselling/therapy, psychological support) 2-3 sessions/week for at least 4 weeks before surgery
Number of subjects: 54
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery as initial management
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality for venous AMI
Number of subjects: 705
Study 38263058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality for NOMI
Number of subjects: 705
Study 38263073 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical epileptiform activity (SEA) detection in AD subjects using LTM-EEG, hd-EEG, and MEG.
Number of subjects: 49
Study 38263073 — intervention group
Group type: EXPERIMENTAL
Intervention: MEG for detecting SEA in AD subjects.
Number of subjects: 49
Study 38263073 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patients with SEA.
Number of subjects: 49
Study 38263073 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patients with SEA compared to those without SEA.
Number of subjects: 49
Study 38263073 — intervention group
Group type: COMPARATOR
Intervention: Cognitively healthy controls (n=24).
Number of subjects: 49
Study 38263088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telephonic case management
Number of subjects: 18
Study 38263088 — intervention group
Group type: COMPARATOR
Intervention: Specialty, outpatient palliative care
Number of subjects: 18
Study 38263142 — intervention group
Group type: EXPERIMENTAL
Intervention: mf-ERG amplitudes of N1, P1 and N2 in ring 1
Number of subjects: 40
Study 38263142 — intervention group
Group type: EXPERIMENTAL
Intervention: Central macular thickness (CMT)
Number of subjects: 40
Study 38263142 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrity of IS/OS junction
Number of subjects: 40
Study 38263142 — intervention group
Group type: EXPERIMENTAL
Intervention: mf-ERG latencies in ring 1
Number of subjects: 40
Study 38263188 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning based prediction model (RISK)
Number of subjects: 0
Study 38263188 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-frequency pressure reactivity index (UL-PRx)
Number of subjects: 263
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral intracranial pressure (ICP)
Number of subjects: 263
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure (CPP)
Number of subjects: 263
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta CPP optimal (ΔCPPopt)
Number of subjects: 263
Study 38263241 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 263